MedTrace Logo

Effect of Eszopiclone on Sleep Disturbance and Pain in Cancer

NCT00365261 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2016-07-11

Study results available
· View outcomes & findings →

Summary

To assess the effectiveness of Lunesta on cancer patients who have received chemotherapy and who require patient controlled analgesia (PCA), specifically to assess whether Lunesta will:

* improve sleep thereby decreasing need for opiates via PCA
* improve sleep thereby decreasing pain by self report
* improve sleep thereby decreasing fatigue by self report

Conditions

  • Sleep Initiation and Maintenance Disorders

Interventions

DRUG

Eszopiclone

eszopiclone 2 to 3 mg po at bedtime

DRUG

Placebo

placebo 2 to 3 mg po at bedtime

Sponsors & Collaborators

Principal Investigators

  • Joel E Dimsdale, MD · UCSD

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-09-30
Primary Completion
2009-12-31
Completion
2009-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00365261 on ClinicalTrials.gov